A new Eli Lilly partnership gives Hims & Hers customers direct access to FDA-approved weight loss dr
Hims & Hers Health just made its most significant move yet in the race to own the weight loss market, and investors responded immediately.
Shares of the telehealth company surged 7 percent after it announced an expanded platform allowing licensed providers to prescribe Eli Lilly’s weight loss medications directly to customers. The deal gives Hims & Hers users access to Zepbound vials and KwikPen, as well as Foundayo, through the LillyDirect pharmacy network at self-pay pricing.
It is a meaningful step for a company that has been aggressively repositioning itself as a serious player in the GLP-1 treatment space, and it arrives at a moment when competition in that market is intensifying rapidly.
What the Eli Lilly deal actually delivers
The partnership gives Hims & Hers providers the ability to route prescriptions for FDA-approved GLP-1 medications directly through LillyDirect, with pricing accessible to Hims & Hers customers.
The company framed the move as part of a broader strategic shift in its U.S. weight loss business, one it says reflects a fundamental transformation in how patients access GLP-1 treatments. The expansion is not happening in isolation. Last month, Hims & Hers announced a separate collaboration with Novo Nordisk giving customers access to Wegovy injections and pills.
The company now has formal relationships with two of the biggest names in the GLP-1 space, and it is positioning those partnerships alongside a membership model that includes 24/7 care team access, personalized nutrition guidance, clinical check-ins and a dedicated peer community.
Why the competitive picture just got more complicated
The 7 percent surge comes at a complicated moment for the stock. Earlier this week, Amazon announced its own GLP-1-based weight management program through Amazon One Medical, a development that placed fresh pressure on Hims & Hers shares and contributed to a 3.83 percent decline before today’s rebound.
For a company whose growth strategy is built heavily on accessible, direct-to-consumer weight loss care, the arrival of Amazon in the same space is not a development investors can dismiss. The Eli Lilly announcement provided a counterweight to that concern, but the underlying competitive dynamic is unlikely to ease anytime soon.
What the technical picture is signaling
The stock’s sharp single-day move also comes with some caution flags for traders watching the technical setup closely. Shares are trading above their 20-day and 50-day moving averages but remain below the 200-day moving average at $38.20, suggesting the longer-term trend has not yet fully recovered. Momentum indicators including the relative strength index and Stochastic RSI are reflecting overbought conditions, which analysts say raises the probability of near-term consolidation.
Analysts have identified a trading range of $27.25 to $29.99 as the most likely zone for the stock over the next five trading days, with a move below the lower end potentially accelerating further declines. A sustained breakout above the upper bound could open the door to renewed upside.
Insider activity adds another layer to watch
While the market was reacting to the Eli Lilly news, a separate regulatory filing showed that Hims & Hers chief legal officer Soleil Boughton sold 9,463 shares of Class A common stock at $30 per share in an open-market transaction conducted under a pre-arranged Rule 10b5-1 trading plan. Boughton retained direct ownership of 299,368 shares following the sale.
Planned insider sales are a routine part of executive compensation structures and do not necessarily signal a negative view of the company’s direction, but they are worth noting alongside the broader picture investors are trying to assess right now.
The stock closed the day at $28.62. With two major GLP-1 partnerships now in place and Amazon entering the conversation, the next few months will reveal whether Hims & Hers has built something durable or simply benefited from a very fast-moving trade.
Disclaimer: This article is for informational purposes only and does not constitute financial advice. The author and publication are not registered investment advisors and do not provide personalized investment recommendations.